Exploratory Study of Breast Cancer With ABY025

Biomedical Radiation Sciences7 enrolled

Overview

The aim is to study if breast cancer metastases accumulate the newly developed HER2 binding molecule 111-In-ABY025 and if that shows whether the metastases express HER2.

Study Type

INTERVENTIONAL

Allocation

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

Conditions

Breast Cancer

Interventions

111-In-ABY-025DRUG

Intravenous injection of the agent

Eligibility

Sex: FEMALEMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: * female age \>20 years * one or more known metastases localizations Exclusion Criteria: * other critical disease than breast cancer * age ≤ 20 years

Locations (1)

Akademiska Hospital

Uppsala, Uppland, Sweden

Outcomes

Primary Outcomes

Imaging of metastases

Imaging of breast cancer metastases using 111-In-ABY015 for SPECT

Time frame: One year

Secondary Outcomes

Can the new molecule be used for imaging in extended studies

Time frame: October 2010 - June 2011

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.